Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 35 Issue 1
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2017  >  35(1): 82-86

ZHAO Jing, CAO Hong, XING Jun-bo. The fingerprint analysis on Chuanshentong injection by HPLC[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 137-139. doi: 10.3969/j.issn.1006-0111.2013.02.016
Citation: JIN Haichao, XING Fangkai, CHEN Tao, LV Wenling. Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
shu

Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis

doi: 10.3969/j.issn.1006-0111.2017.01.021
  • 1.

    The 71571 Unit of PLA, Yantai 265500, China

  • 2.

    The Gynecology & Obstetrics of Yuhuangding Hospital, Yantai 265000, China

  • Received Date: 2016-03-07
  • Rev Recd Date: 2016-07-18
  • Objective To evaluate the efficacy and safety of amrubicin for small-cell lung cancer(SCLC). Methods PubMed, Embase, the Cochrane Library and CNKI were searched to collect amrubicin data in the treatment of SCLC. A Meta-analysis was performed over the published clinical trials. The efficacy and safety of amrubicin were evaluated based on overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity. Results Our analysis for 6 clinical trials indicated that amrubicin had significantly higher ORR than control group[RR 1.72,95% CI (1.39, 2.14),P=0.000], the OS, PFS and toxicity were no-inferior to the control group(P=0.405,P=0.456). Conclusion Amrubicin can be considered as a good second-line treatment for relapsed SCLC.
  • [1] Cheng S, Evans WK, Stys-Norman D, et al. Chemotherapy for relapsed small cell lung cancer:a systematic review and practice guideline[J]. J Thorac Oncol, 2007,2(4):348-354.
    [2] Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC)[J]. Cancer Treat Rev, 2011,37(2):143-150.
    [3] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology:a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group[J]. JAMA, 2000,283(15):2008-2012.
    [4] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010,25(9):603-605.
    [5] O'Brien ME, Konopa K, Lorigan P, et al. Randomised phase Ⅱ study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer-EORTC 08062[J]. Eur J Cancer, 2011,47(15):2322-2330.
    [6] Satouchi M, Kotani Y, Shibata T, et al. Phase Ⅲ study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer:JCOG 0509[J]. J Clin Oncol, 2014,32(12):1262-1268.
    [7] Sekine I, Okamoto H, Horai T, et al. A randomized phase Ⅲ study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer[J]. Clin Lung Cancer, 2014,15(2):96-102.
    [8] Wakuda K, Kenmotsu H, Naito T, et al. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer[J]. Am J Clin Oncol, 2015,38(1):28-32.
    [9] Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase Ⅱ trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer:North Japan Lung Cancer Study Group Trial 0402[J]. J Clin Oncol, 2008,26(33):5401-5406.
    [10] Inoue A, Sugawara S, Maemondo M, et al. Randomized phase Ⅱ trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer:North Japan Lung Cancer Study Group trial 0702[J]. Lung Cancer, 2015, 89(1):61-65.
    [11] Jotte R, Conkling P, Reynolds C, et al. Randomized phase Ⅱ trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy[J]. J Clin Oncol, 2011,29(3):287-293.
    [12] von Pawel J, Jotte R, Spigel DR, et al. Randomized phase Ⅲ trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer[J]. J Clin Oncol, 2014,32(35):4012-4019.
    [13] Tani N, Yabuki M, Komuro S, et al. Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride[J]. Xenobiotica, 2005,35(12):1121-1133.
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-040Highcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 85.9 %FULLTEXT: 85.9 %META: 12.8 %META: 12.8 %PDF: 1.3 %PDF: 1.3 %FULLTEXTMETAPDFHighcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 28.6 %其他: 28.6 %Singapore: 0.2 %Singapore: 0.2 %United States: 0.2 %United States: 0.2 %上海: 2.1 %上海: 2.1 %北京: 11.8 %北京: 11.8 %十堰: 0.2 %十堰: 0.2 %南京: 0.2 %南京: 0.2 %密蘇里城: 0.4 %密蘇里城: 0.4 %成都: 0.6 %成都: 0.6 %杭州: 0.6 %杭州: 0.6 %武汉: 0.2 %武汉: 0.2 %沈阳: 0.2 %沈阳: 0.2 %沧州: 0.2 %沧州: 0.2 %盐城: 0.2 %盐城: 0.2 %聊城: 0.4 %聊城: 0.4 %芒廷维尤: 13.9 %芒廷维尤: 13.9 %西宁: 37.4 %西宁: 37.4 %西安: 0.2 %西安: 0.2 %运城: 0.4 %运城: 0.4 %郑州: 0.2 %郑州: 0.2 %鄂州: 0.2 %鄂州: 0.2 %长沙: 0.2 %长沙: 0.2 %长治: 0.2 %长治: 0.2 %黄冈: 1.1 %黄冈: 1.1 %其他SingaporeUnited States上海北京十堰南京密蘇里城成都杭州武汉沈阳沧州盐城聊城芒廷维尤西宁西安运城郑州鄂州长沙长治黄冈Highcharts.com

  • Cited by

    Periodical cited type(8)

    1. 林新，王诗宝，何焕清，李钦艳，钟莹莹，陈逸湘，肖自添，凌宏通，曹斌，林苑云. 广东省梅州市紫灵芝产业现状与发展对策. 中国食用菌. 2023(04): 115-119 .
    2. 张碧云，陆敏. 灵芝在慢性萎缩性胃炎治疗中的应用进展. 云南中医中药杂志. 2022(09): 80-83 .
    3. 李亚晗，刘佳琳，王天添，刘玟妍，孙丽媛，李明成. 灵芝多糖抗肿瘤免疫调节机制的研究进展. 中国免疫学杂志. 2021(04): 511-514 .
    4. 赵玲. 灵芝多糖在运动员抗脂质过氧化中的作用. 中国食用菌. 2021(02): 75-79 .
    5. 田义敏，周欣，赵超，陈华国，龚小见. 中药有效成分抗胃癌作用机制的研究进展. 中国中药杂志. 2020(15): 3584-3593 .
    6. 王雪妍，周伏忠，向凌云，陈晓飞，宁萌，刁文涛. 灵芝免疫调节蛋白LZ-8及云芝免疫调节蛋白FIP-tvc对几种癌细胞系的抑制活性检测. 河南科学. 2019(06): 914-918 .
    7. 刘玲，李奇璋，周选围，王玉亮. 重组黑芝免疫调节蛋白对小鼠巨噬细胞RAW264.7向M1型分化的影响. 食品科学. 2019(23): 170-175 .
    8. 何嘉烽，吴小勇，尹辉，李文治，何文江. 水溶性灵芝粉的制备及其免疫调节活性评价. 广东药科大学学报. 2018(03): 288-292 .

    Other cited types(5)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(3524) PDF downloads(868) Cited by(13)

Related
Proportional views

Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis

doi: 10.3969/j.issn.1006-0111.2017.01.021
  • 1. The 71571 Unit of PLA, Yantai 265500, China
  • 2. The Gynecology & Obstetrics of Yuhuangding Hospital, Yantai 265000, China
  • Received Date: 2016-03-07
  • Rev Recd Date: 2016-07-18

Abstract: Objective To evaluate the efficacy and safety of amrubicin for small-cell lung cancer(SCLC). Methods PubMed, Embase, the Cochrane Library and CNKI were searched to collect amrubicin data in the treatment of SCLC. A Meta-analysis was performed over the published clinical trials. The efficacy and safety of amrubicin were evaluated based on overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity. Results Our analysis for 6 clinical trials indicated that amrubicin had significantly higher ORR than control group[RR 1.72,95% CI (1.39, 2.14),P=0.000], the OS, PFS and toxicity were no-inferior to the control group(P=0.405,P=0.456). Conclusion Amrubicin can be considered as a good second-line treatment for relapsed SCLC.

ZHAO Jing, CAO Hong, XING Jun-bo. The fingerprint analysis on Chuanshentong injection by HPLC[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 137-139. doi: 10.3969/j.issn.1006-0111.2013.02.016
Citation: JIN Haichao, XING Fangkai, CHEN Tao, LV Wenling. Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
shu

    HTML

Reference (13)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return